Irosustat
Alternative Names: 6,6,7-COUMATE; BN 83495; Irostustat; oristusane; STX 64PC; STX-64Latest Information Update: 05 Nov 2023
At a glance
- Originator Ipsen
- Developer Ipsen; Peter MacCallum Cancer Centre
- Class Antineoplastics; Sulfonic acids
- Mechanism of Action Steryl sulfatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Discontinued Breast cancer; Endometrial cancer; Non-small cell lung cancer; Prostate cancer; Solid tumours
Most Recent Events
- 11 Mar 2016 Discontinued - Phase-II for Breast cancer (Neoadjuvant therapy) in United Kingdom (PO)
- 11 Mar 2016 Ipsen terminates phase II trial in Breast cancer (Neoadjuvant therapy) in United Kingdom (NCT01662726)
- 13 Aug 2015 No recent reports on development identified - Phase-II for Breast cancer (Neoadjuvant therapy) in United Kingdom (PO)